AMRI will cease Discovery and Development Services (DDS) operations at its Syracuse, NY site by the end of June 2014. The company will transition these activities to other sites as part of an effort to consolidate facility resources and reduce costs.
 
AMRI’s Syracuse site provides chemical process R&D, custom chemical synthesis and scale-up of pharmaceuticals intermediates and final products. As part of the transition, Syracuse DDS capabilities and some employees will be transferred to several AMRI facilities, including Albany, NY; Cedarburg, WI; Holywell, UK and Hyderabad, India.
 
The company estimates that it will incur charges between $5.8 – $6.5 million related to workforce reductions and transition activities, the majority of which will be recorded in the second and third quarters of 2014. AMRI expects to generate annual savings of approximately $1.5 million.
 
“The decision we have made, while difficult for our colleagues in Syracuse, reflects the continued evolution of AMRI’s business to better align our operations to most efficiently support our customer needs, while preserving the skills and capabilities that our customers demand as they return to greater utilization of their outsourcing partners,” said William S. Marth, AMRI’s president and chief executive officer. “We remain committed to our total integrated discovery and development services platform and the capabilities for which Syracuse has become distinguished, and we will be transitioning and consolidating those activities to other sites within AMRI.”